Jakafi (ruxolitinib)
Myelofibrosis
About Incyte
Incyte is a publicly traded, revenue-generating biopharmaceutical company with a market valuation of approximately $18.19 billion, built on a foundation of targeted small molecule science. Its commercial success is anchored by Jakafi® (ruxolitinib) in myelofibrosis and polycythemia vera, with a diversified pipeline extending into oncology and immunology. The company's strategy combines internal R&D excellence with strategic partnerships to expand its therapeutic footprint and commercial reach globally.
View full company profileAbout Incyte
Incyte is a publicly traded, revenue-generating biopharmaceutical company with a market valuation of approximately $18.19 billion, built on a foundation of targeted small molecule science. Its commercial success is anchored by Jakafi® (ruxolitinib) in myelofibrosis and polycythemia vera, with a diversified pipeline extending into oncology and immunology. The company's strategy combines internal R&D excellence with strategic partnerships to expand its therapeutic footprint and commercial reach globally.
View full company profileAbout Incyte
Incyte is a publicly traded, revenue-generating biopharmaceutical company with a market valuation of approximately $18.19 billion, built on a foundation of targeted small molecule science. Its commercial success is anchored by Jakafi® (ruxolitinib) in myelofibrosis and polycythemia vera, with a diversified pipeline extending into oncology and immunology. The company's strategy combines internal R&D excellence with strategic partnerships to expand its therapeutic footprint and commercial reach globally.
View full company profileTherapeutic Areas
Other Myelofibrosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Tasquinimod | Active Biotech | Phase Ib/IIa |
| Zavabresib (OPN-2853) | Opna Bio | Phase 1 |
| Exploratory Program | Cellarity | Pre-clinical |
| Myelofibrosis Program | Sequantrix | Pre-clinical |
| KER-050 (Eltritercept) | Keros Therapeutics | Phase 2 |
| Selinexor | Karyopharm Therapeutics | Phase 3 |